Stephens Investment Management Group LLC Increases Stake in DexCom, Inc. (NASDAQ:DXCM)

Stephens Investment Management Group LLC raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 2.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 703,919 shares of the medical device company’s stock after acquiring an additional 19,434 shares during the quarter. Stephens Investment Management Group LLC’s holdings in DexCom were worth $54,744,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Versant Capital Management Inc bought a new stake in shares of DexCom in the fourth quarter valued at approximately $25,000. Riverview Trust Co raised its holdings in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares during the period. Heck Capital Advisors LLC bought a new stake in DexCom during the 4th quarter valued at $38,000. RPg Family Wealth Advisory LLC purchased a new stake in shares of DexCom during the third quarter worth $57,000. Finally, Covestor Ltd boosted its holdings in shares of DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after acquiring an additional 335 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Trading Down 0.3 %

Shares of DXCM opened at $88.08 on Friday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The firm has a 50 day moving average price of $81.76 and a 200-day moving average price of $75.62. The firm has a market cap of $34.40 billion, a price-to-earnings ratio of 52.74, a PEG ratio of 2.26 and a beta of 1.14.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on DXCM shares. Leerink Partners reduced their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Canaccord Genuity Group boosted their target price on DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Finally, Wells Fargo & Company lifted their price target on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $98.41.

Insiders Place Their Bets

In related news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Sadie Stern sold 4,259 shares of the stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,342 shares of company stock valued at $3,628,069 over the last three months. Insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.